Human B7-2 / CD86 Protein, His Tag

Proteins and Peptides

貨號 Cat. No.
CD6-H5223
規格 Size
100ug
品牌 Brand
ACROBiosystems
Species
Human
Conjugate
Unconjugated
Expression System
HEK293
Tag
His Tag

Description




Source : 


Human B7-2, His Tag (CD6-H5223) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).


 

Molecule : B7-2


 

Synonyms : CD86,B7-2,B70,CD28LG2,LAB72,MGC34413


 

Format : Powder


 

Category : Immune Checkpoint Proteins


 

Accession : AAH40261


 

Storage : -20℃


 

Shipping condition : Powder,RT


 

Molecular Weight : 26.2 kDa


 

Characteristics :


This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 26.2 kDa. The protein migrates as 42-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.


 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.


 

Buffer : PBS, pH7.4


 

Description :


Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.


 

References :


(1) Chen C, et al., 1994, J. Immunol. 152 (10): 4929–36.
(2) Yadav, D. et al., 2007, J. Immunol. 178: 6236-6241.
(3) Steidl C, et al., 2010, N. Engl. J. Med. 362 (10): 875–85.





詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢